Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, Canada.
Eur J Haematol. 2024 Nov;113(5):576-583. doi: 10.1111/ejh.14267. Epub 2024 Jul 10.
Adult-onset Still's disease (AOSD) and secondary hemophagocytic lymphohistiocytosis (sHLH) are both hyperferritinemic cytokine storm syndromes that can be difficult to distinguish from each other in hospitalized patients. The objective of this study was to compare the inflammatory markers ferritin, D-dimer, C-reactive protein (CRP), and soluble CD25 (sCD25) in patients with AOSD and sHLH. These four markers were chosen as they are widely available and represent different aspects of inflammatory diseases: macrophage activation (ferritin); endothelialopathy (D-dimer); interleukin-1/interleukin-6/tumour necrosis factor elevation (CRP) and T cell activation (sCD25).
This was a single-center retrospective study. Patients diagnosed by the Hematology service at Vancouver General Hospital for AOSD or sHLH from 2009 to 2023 were included.
There were 16 AOSD and 44 sHLH patients identified. Ferritin was lower in AOSD than HLH (median 11 360 μg/L vs. 29 020 μg/L, p = .01) while D-dimer was not significantly different (median 5310 mg/L FEU vs. 7000 mg/L FEU, p = .3). CRP was higher (median 168 mg/L vs. 71 mg/L, p <.01) and sCD25 was lower (median 2220 vs. 7280 U/mL, p = .004) in AOSD compared to HLH. The combined ROC curve using CRP >130 mg/L and sCD25< 3900 U/mL to distinguish AOSD from HLH had an area under the curve (AUC) of 0.94 (95% confidence interval 0.93-0.97) with sensitivity 91% and specificity 93%.
These findings suggest that simple, widely available laboratory tests such as CRP and sCD25 can help clinicians distinguish AOSD from HLH in acutely ill adults with extreme hyperferritinemia. Larger studies examining a wider range of clinically available inflammatory biomarkers in a more diverse set of cytokine storm syndromes are warranted.
成人Still 病(AOSD)和继发性噬血细胞性淋巴组织细胞增生症(sHLH)都是高血清铁蛋白细胞因子风暴综合征,在住院患者中很难将两者区分开来。本研究旨在比较 AOSD 和 sHLH 患者的炎症标志物铁蛋白、D-二聚体、C 反应蛋白(CRP)和可溶性 CD25(sCD25)。选择这四个标志物是因为它们广泛可用,代表了炎症疾病的不同方面:巨噬细胞活化(铁蛋白);内皮病(D-二聚体);白细胞介素 1/白细胞介素 6/肿瘤坏死因子升高(CRP)和 T 细胞活化(sCD25)。
这是一项单中心回顾性研究。2009 年至 2023 年,温哥华综合医院血液科诊断为 AOSD 或 sHLH 的患者纳入本研究。
共纳入 16 例 AOSD 和 44 例 sHLH 患者。与 sHLH 相比,AOSD 患者的铁蛋白水平较低(中位数 11360μg/L 比 29020μg/L,p=0.01),而 D-二聚体无显著差异(中位数 5310mg/L FEU 比 7000mg/L FEU,p=0.3)。与 sHLH 相比,AOSD 患者的 CRP 更高(中位数 168mg/L 比 71mg/L,p<0.01),sCD25 更低(中位数 2220 比 7280U/mL,p=0.004)。使用 CRP>130mg/L 和 sCD25<3900U/mL 来区分 AOSD 和 sHLH 的联合 ROC 曲线下面积(AUC)为 0.94(95%置信区间 0.93-0.97),灵敏度为 91%,特异性为 93%。
这些发现表明,CRP 和 sCD25 等简单、广泛可用的实验室检测可以帮助临床医生在急性重病且血清铁蛋白极高的成人中区分 AOSD 和 sHLH。需要更大规模的研究来检查更广泛的、临床上可用的炎症生物标志物在更广泛的细胞因子风暴综合征中的作用。